Christine Simmon: GRx+Biosims Combines Three Events into One
Christine Simmon, AAM Senior Vice President of Policy and Strategic Alliances and Executive Director of the Biosimilars Council, invites industry professionals to attend GRx+Biosims 2018 on Sept. 5-7 in Baltimore, MD. This year, we are combining FallTech, Leading on Biosimilars, and CMC Workshop to one can't-miss opportunity to connect with peers around the world. Attend GRx+Biosims to hear the latest from top-in-their-field speakers and government officials, share best practices and discover new learning tracks in the generic and biosimilars industry.
Christine Simmon Reacts to the Release of FDA's Biosimilars Action Plan
Christine Simmon, Executive Director of AAM's Biosimilars Council, reacts to the recent release of FDA's Biosimilars Action Plan
AAM Statement on FDA’s Biosimilars Action Plan
Agency’s Commitment to Competition, Efficient Development and Approval Process Lauded
AAM Responds to President Trump's Speech on Lowering Prescription Drug Prices
The Biosimilars Council Congressional Briefing: Five Takeaways
Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion with Molly Burich (Boehringer Ingelheim), Mark Fleury (American Cancer Society’s Cancer Action Network), Greg Gierer (America’s Health Insurance Plans) and Patrick Vallano (Mylan).
A Conference You Don't Want to Miss — GRx+Biosims 2018
Biosimilars Handbook
The New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products
Biosimilars hold the key to ensuring affordable access to biologic medicines for all consumers. The Biosimilars Council exists to educate, advocate, and promote the development of these products through resources such as this handbook.
This handbook is designed to be a reference tool for health care professionals as well as patients interested in learning more about biosimilars and interchangeable biologics.
Policy Recommendations to Develop a Robust Biosimilars Market in the U.S.
Biosimilars have the potential to improve quality of life for patients. If the right policies are put in place to cultivate a robust market, an additional 1.2 million patients will have access to biologic medicines, while also saving an estimated $54 billion over the next 10 years.